Open AccessIs dapsone still relevant in immune thrombocytopenia in resource limited settings?
Author(s) -
Preeti Dalal,
Manisha Gulia,
Meena Gupta,
Anita Tahlan
Publication year - 2019
Publication title -
bmj case reports
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.231
H-Index - 26
ISSN - 1757-790X
DOI - 10.1136/bcr-2019-232217
Subject(s) - medicine , dapsone , thrombopoiesis , thrombopoietin , immune thrombocytopenia , thrombocytopenic purpura , autoantibody , immune system , immunology , drug , platelet , antibody , eltrombopag , pharmacology , megakaryocyte , stem cell , haematopoiesis , biology , genetics
Immune thrombocytopenia is an autoimmune disorder characterised by autoantibody production against platelets, increased platelet destruction and impaired thrombopoiesis. Steroids are the first-line agents whenever treatment is indicated; however, some patients may not respond and the responders may as well relapse while the dose is being tapered. Side effects of steroids prohibits their long-term use and patients often have to be switched to other agents. Standard drug management with intravenous immunoglobulins and thrombopoietin receptor analogues is difficult to administer in patients from low socioeconomic regions of the world making the management even more challenging. Hence, after reviewing the literature and considering the cost in comparison to all the second-line agents available, we tried dapsone in a steroid-dependent patient of immune thrombocytopenic purpura who had developed major steroid-related side effects. Patient showed good response to dapsone and has been in remission for around one and a half years.